Beijing Surgerii Technology Co., Ltd. announced that it has received $31 million in funding from Medtronic plc, Shunwei, Inc., SDIC Capital Co.,Ltd, V Star Capital, Shanghai Biomedical Industry Equity Fund Management Co., Ltd.
June 31, 2022
Share
Beijing Surgerii Technology Co., Ltd. has received series C funding of $31 million on June 1, 2022.
The round was lead by new investor, Shanghai Biomedical Industry Equity Fund Management Co., Ltd..
The transaction also saw participation from new investors, SDIC Capital Co.,Ltd , V Star Capital, and existing investors, Shunwei, Inc. and Medtronic plc.
Medtronic plc is one of the world leaders in designing, manufacturing and marketing of medical equipment. Net sales break down by sector of activity as follows:
- general and minimally invasive surgery (28.8%): surgical equipment, intra-operative monitoring systems, ventilation systems, etc.;
- cardiac rhythm management (18.6%): implantable cardiac pacemakers, implantable defibrillators and automatic external defibrillators, cardiac ablation probes, etc.;
- vascular diseases and cardiac surgery (17.4%): coronary stents, endoprostheses for aortal pathologies, distal protection systems, catheters, heart valve prostheses, auto-transfusion equipment, cardiac ablation devices, etc.;
- spinal disorders (14.1%): spinal prostheses, disc prostheses, cerebral stimulation systems, bone graft technologies and mini-invasive spinal surgery, etc. The group also develops medical imagery-guided surgical navigation systems activity;
- neurovascular, ear, nose and throat (ENT) and pelvic diseases (8.2%);
- diabetes management (7.4%): internal and external glycemia monitoring systems and insulin pumps;
- neurological disorders (5.5%): neurostimulation and pumped medication administration products, diagnostic tools, etc.
Net sales are distributed geographically as follows: Ireland (0.3%), the United States (50.9%) and other (48.8%).
Beijing Surgerii Technology Co., Ltd. announced that it has received $31 million in funding from Medtronic plc, Shunwei, Inc., SDIC Capital Co.,Ltd, V Star Capital, Shanghai Biomedical Industry Equity Fund Management Co., Ltd.